The California biotech is shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and focus on its lead antibody-drug conjugate.
After hours: March 20 at 7:43:41 PM EDT Loading Chart for VOR ...
After hours: March 19 at 7:55:27 PM EDT Loading Chart for CLRB ...